Platelet-derived Growth Factor and Its Receptor Expression in Human Oligodendrogliomas

Neurosurgery ◽  
1998 ◽  
Vol 42 (2) ◽  
pp. 346-346
Author(s):  
James T. Rutka
2014 ◽  
Vol 55 (2) ◽  
pp. 294-300 ◽  
Author(s):  
V. Tolmachev ◽  
Z. Varasteh ◽  
H. Honarvar ◽  
S. J. Hosseinimehr ◽  
O. Eriksson ◽  
...  

2009 ◽  
Vol 175 (1) ◽  
pp. 334-341 ◽  
Author(s):  
Janna Paulsson ◽  
Tobias Sjöblom ◽  
Patrick Micke ◽  
Fredrik Pontén ◽  
Göran Landberg ◽  
...  

1995 ◽  
Vol 15 (3) ◽  
pp. 1244-1253 ◽  
Author(s):  
C Vaziri ◽  
D V Faller

Platelet-derived growth factor BB (PDGF-BB) is an important extracellular factor for regulating the G0-S phase transition of murine BALB/c-3T3 fibroblasts. We have investigated the expression of the PDGF beta receptor (PDGF beta R) in these cells. We show that the state of growth arrest in G0, resulting from serum deprivation, is associated with increased expression of the PDGF beta R. When the growth-arrested fibroblasts are stimulated to reenter the cell cycle by the mitogenic action of serum or certain specific combinations of growth factors, PDGF beta R mRNA levels and cell surface PDGF-BB-binding sites are markedly downregualted. Oncogene-transformed 3T3 cell lines, which fail to undergo growth arrest following prolonged serum deprivation, express constitutively low levels of the PDGF beta R mRNA and possess greatly reduced numbers of cell surface PDGF receptors, as determined by PDGF-BB binding and Western blotting (immunoblotting). Nuclear runoff assays indicate the mechanism of repression of PDGF beta R expression to be, at least in large part, transcriptional. These data indicate that expression of the PDGF beta R is regulated in a growth state-dependent manner in fibroblasts and suggest that this may provide a means by which cells can modulate their responsiveness to the actions of PDGF.


2016 ◽  
Vol 54 (2) ◽  
pp. 212-217 ◽  
Author(s):  
G. Avallone ◽  
V. Pellegrino ◽  
P. Roccabianca ◽  
E. Lepri ◽  
L. Crippa ◽  
...  

The expression of tyrosine kinase receptors is attracting major interest in human and veterinary oncological pathology because of their role as targets for adjuvant therapies. Little is known about tyrosine kinase receptor (TKR) expression in canine liposarcoma (LP), a soft tissue sarcoma. The aim of this study was to evaluate the immunohistochemical expression of the TKRs fibroblast growth factor receptor 1 (FGFR1) and platelet-derived growth factor receptor–β (PDGFRβ); their ligands, fibroblast growth factor 2 (FGF2) and platelet-derived growth factor B (PDGFB); and c-kit in canine LP. Immunohistochemical labeling was categorized as high or low expression and compared with the mitotic count and MIB-1–based proliferation index. Fifty canine LPs were examined, classified, and graded. Fourteen cases were classified as well differentiated, 7 as myxoid, 25 as pleomorphic, and 4 as dedifferentiated. Seventeen cases were grade 1, 26 were grade 2, and 7 were grade 3. A high expression of FGF2, FGFR1, PDGFB, and PDGFRβ was identified in 62% (31/50), 68% (34/50), 81.6% (40/49), and 70.8% (34/48) of the cases, respectively. c-kit was expressed in 12.5% (6/48) of the cases. Mitotic count negatively correlated with FGF2 ( R = –0.41; P < .01), being lower in cases with high FGF2 expression, and positively correlated with PDGFRβ ( R = 0.33; P < .01), being higher in cases with high PDGFRβ expression. No other statistically significant correlations were identified. These results suggest that the PDGFRβ-mediated pathway may have a role in the progression of canine LP and may thus represent a promising target for adjuvant cancer therapies.


2012 ◽  
Vol 511 (2) ◽  
pp. 65-69 ◽  
Author(s):  
Maryam S. Vasefi ◽  
Jeff S. Kruk ◽  
Hui Liu ◽  
John J. Heikkila ◽  
Michael A. Beazely

Sign in / Sign up

Export Citation Format

Share Document